Literature DB >> 25961699

Twenty years of modelling NPM-ALK-induced lymphomagenesis.

Sylvie Giuriato, Suzanne D Turner1.   

Abstract

Our current understanding of oncogenic Anaplastic Lymphoma Kinase (ALK)-induced lymphomagenesis has relied for over 20 years on multiple and complementary studies performed on various experimental models, encompassing ALK oncogene expressing cells, their grafts into immune-compromised mice, the generation of genetically engineered mouse models (GEMMs) and, when available, the use of patient samples from Anaplastic Large Cell Lymphoma (ALCL) tumour banks. Of note, and to our knowledge, no ALK-positive ALCL 3D culture system has been described so far. In this review, we will first outline how these different cell and mouse models were designed, and what key findings they revealed (or confirmed) towards oncogenic ALK-induced lymphomagenesis. Secondly, we will discuss how recent and revolutionary advances in genetic engineering technology are likely to complete our understanding of ALK-related disease in an effort to improve current therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25961699     DOI: 10.2741/S437

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN: 1945-0516


  2 in total

Review 1.  From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL).

Authors:  Michael T Werner; Qian Zhang; Mariusz A Wasik
Journal:  Cancers (Basel)       Date:  2017-10-16       Impact factor: 6.639

2.  Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.

Authors:  Géraldine Mitou; Julie Frentzel; Aurore Desquesnes; Sophie Le Gonidec; Talal AlSaati; Isabelle Beau; Laurence Lamant; Fabienne Meggetto; Estelle Espinos; Patrice Codogno; Pierre Brousset; Sylvie Giuriato
Journal:  Oncotarget       Date:  2015-10-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.